News

Kadans Science Partner adds to Oxfordshire’s laboratory supply with the completion of Barton House

• Key deals cause a surge in Golden Triangle leasing activity, bolstered by the 352,000 sq ft transacted in final quarter of last year

• Development pipeline totals 3.1 million sq ft across Golden Triangle


Demand for life sciences space in the ‘Golden Triangle’ surged in 2023, with the 925,000 sq ft of space representing the highest annual volume since 2015, according to the latest figures from Cushman & Wakefield.

Pioneer Group, a leading developer and operator of life science and high-tech campuses, has secured planning permission from Cambridge City Council, subject to S106, for the redevelopment of the Grafton Centre in the city.


The Planning Committee at Cambridge City Council yesterday (7 Feb) voted in favour of the multi-million-pound regeneration for the shopping centre, which will be converted into laboratory and office space for life science and tech companies. The western end of the centre will be retained and transformed into a more attractive destination for local shoppers.

Read February eNews: Where to find Your Life Science Connections, featuring:


✅ Welcome from Tony Jones, CEO, One Nucleus


✅ Moving Forward Together


✅ Is it Rocket Science? 


✅ Use One Nucleus' High Profile Initiatives to Reach Your Audience


✅ Narrowing the Odds on Success


✅ Nominate Your Life Sciences Inspiration of the Year Award 2024


✅ Upcoming Events for Your Diary


New NGS Laboratory opens its doors for genomics researchers.


Azenta Life Sciences will officially open its new GENEWIZ Multiomics and Synthesis Solutions laboratory in Oxford, UK in March 2024. As a global provider of R&D genomics services, Azenta leads the way in providing superior data quality with unparalleled technical support to enable researchers around the world to advance their scientific discoveries faster than ever before.

1 February 2024 - Cambridge, UK - Maxion Therapeutics (“Maxion”), the biotechnology company developing antibody-based drugs for previously untreatable ion channel- and GPCR-driven diseases, announced today that Dr Arndt Schottelius has been appointed as the new Chief Executive Officer, effective on 1 March 2024, to take the Company to its next phase of development.

29 February 2024 | The Garden Room, St John’s Innovation Centre, Cambridge


It’s never too early to start planning your business exit. Business exit strategy experts Yellowyoyo have teamed up with Innovate UK EDGE to deliver an essential event for founders that will set you on the road to maximising value, whether you plan to exit in five years or fifty years. Do you plan to sell your business, pass it to your chosen successor, merge with another company or stay on in a new role? Whatever your preferred exit, the time to start preparing is now.

CN Bio appoints Joseph Parisi as US Director of Sales to support accelerated growth in key OOC market

Pages